Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HepaStem Long-Term Safety Registry (PROLONGSTEM)
2022-500251-22-00Phase 2Completed
- Sponsor
- Cellaïon
- Start
- Feb 2023
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 6
01
Overview
Phase 2, open-label, single-arm trial of hepastem in urea cycle disorder (UCD), Crigler-Najjar syndrome (CNS) and IgG4-related hepatobiliary disease (IgG4-RHD), sponsored by Cellaïon. Started Feb 2023; status: completed.
02
Drugs
hepastem
03
Conditions
urea cycle disorder (UCD)Crigler-Najjar syndrome (CNS)IgG4-related hepatobiliary disease (IgG4-RHD)
Beyond the preview
Go deeper on 2022-500251-22-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-500251-22-00.